SCHEMBL4012685

SCHEMBL4012685

C=C/C=C(\C(=O)OC)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.47
TDP1 Q9NUW8 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 4/20 0.43
AKT1 P31749 2/20 0.42
ALDH1A1 P00352 5/20 0.41
HPGD P15428 2/20 0.41
HTT P42858 1/20 0.41
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
SRC P12931 1/20 0.40
AKR1C1 Q04828 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP3A4 P08684 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4012690 1.00 TSHR (0.47) TSHRTDP1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL9688036 0.82 AKT1 (0.42) TSHRTDP1KDM4ELMNAAKT1
SCHEMBL7807838 0.81 TSHR (0.54) TSHRTDP1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL2048794 0.81 TSHR (0.54) TSHRTDP1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL4013088 0.81 TSHR (0.54) TSHRTDP1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL11402660 0.79 CES2 (0.48) TSHRTDP1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL11402663 0.79 CES2 (0.48) TSHRTDP1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL9738478 0.79 TSHR (0.52) TSHRTDP1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL9738473 0.79 TSHR (0.52) TSHRTDP1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL13116685 0.79 TSHR (0.52) TSHRTDP1L3MBTL1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781617-A4 ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 EP disclosed
EP-1781617-A2 ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-09 EP disclosed
WO-2006004742-A2 α, β-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARAMCEUTICA N.V. (BE) 2006-01-12 WO disclosed
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration CCKAR, CCKBR, FFAR1 TSHR 301/4885TDP1 4321/4885L3MBTL1 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.